- Home
- LUXE vs OCS Comparison
LUXE vs OCS Comparison
Compare LUXE & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUXE
- OCS
- Stock Information
- Founded
- LUXE 1987
- OCS 2003
- Country
- LUXE Germany
- OCS Switzerland
- Employees
- LUXE N/A
- OCS N/A
- Industry
- LUXE
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- LUXE
- OCS Health Care
- Exchange
- LUXE NYSE
- OCS Nasdaq
- Market Cap
- LUXE 1.0B
- OCS 956.4M
- IPO Year
- LUXE N/A
- OCS N/A
- Fundamental
- Price
- LUXE $8.21
- OCS $17.96
- Analyst Decision
- LUXE
- OCS Strong Buy
- Analyst Count
- LUXE 0
- OCS 3
- Target Price
- LUXE N/A
- OCS $35.33
- AVG Volume (30 Days)
- LUXE 141.4K
- OCS 12.2K
- Earning Date
- LUXE 09-11-2025
- OCS 08-26-2025
- Dividend Yield
- LUXE N/A
- OCS N/A
- EPS Growth
- LUXE N/A
- OCS N/A
- EPS
- LUXE N/A
- OCS N/A
- Revenue
- LUXE $962,367,055.00
- OCS $847,333.00
- Revenue This Year
- LUXE $48.06
- OCS $10.23
- Revenue Next Year
- LUXE $114.70
- OCS $912.87
- P/E Ratio
- LUXE N/A
- OCS N/A
- Revenue Growth
- LUXE 8.74
- OCS N/A
- 52 Week Low
- LUXE $3.22
- OCS $10.79
- 52 Week High
- LUXE $12.50
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- LUXE N/A
- OCS 44.00
- Support Level
- LUXE N/A
- OCS $17.22
- Resistance Level
- LUXE N/A
- OCS $18.09
- Average True Range (ATR)
- LUXE 0.00
- OCS 0.53
- MACD
- LUXE 0.00
- OCS -0.03
- Stochastic Oscillator
- LUXE 0.00
- OCS 36.63
About LUXE LUXEXPERIENCE B.V. SPON ADS EACH RE SPON ADS EACH REP 1 ORD SHS
LuxExperience BV is the digital, multi-brand luxury group and the online shopping destination for luxury enthusiasts. The group operates a portfolio of some of the distinguished store brands in digital luxury and creates communities for luxury enthusiasts with digital and physical experiences. Its brands are MYTHERESA, NET-A-PORTER, MR PORTER, YOOX, and THE OUTNET.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.